UB Paderborn / Katalog / Suche / in CDI

Effect of STING agonist on tumor immune microenvironment of non-inflamed lung cancer and efficacy of immune checkpoint blockade

Journal of clinical oncology, 2018-02, Vol.36 (5_suppl), p.178-178

Chon, Hongjae

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract 5637: Combination of oncolytic vaccinia virus and immune checkpoint blockade overcomes resistance to immunotherapy in renal cell carcinoma

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.5637-5637

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract A061: STING, an immune biomarker for colorectal cancer

Cancer immunology research, 2019-02, Vol.7 (2_Supplement), p.A061-A061

2019

Link zum Volltext

Verfügbarkeit prüfen

Phase II trial of second-line regorafenib in patients with unresectable hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab: REGONEXT trial

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.TPS634-TPS634

2023

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of nivolumab and ipilimumab in patients with hepatocellular carcinoma with prior immune-checkpoint inhibitor treatment

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.554-554

2023

Link zum Volltext

Verfügbarkeit prüfen

Organ-specific responses to atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.4076-4076

2022

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of nab-paclitaxel plus gemcitabine-cisplatin (GemCis/nab-P) in Korean patients with advanced biliary tract cancers (aBTC): Multicenter retrospective analysis

Journal of clinical oncology, 2021-01, Vol.39 (3_suppl), p.274-274

2021

Link zum Volltext

Verfügbarkeit prüfen

Clinical feasibility of curative surgery after nab-paclitaxel plus gemcitabine-cisplatin chemotherapy in patients with locally advanced cholangiocarcinoma

Journal of clinical oncology, 2022-02, Vol.40 (4_suppl), p.387-387

2022

Link zum Volltext

Verfügbarkeit prüfen

Correlation of high serum interleukin-6 with clinical outcome and T cell response in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.596-596

2023

Link zum Volltext

Verfügbarkeit prüfen

Artificial intelligence (AI)-powered immune phenotyping to predict outcomes of immuno-oncology (IO)-based regimens in hepatocellular carcinoma (HCC)

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.601-601

2023

Link zum Volltext

Verfügbarkeit prüfen

Abstract 4884: Intratumoral high endothelial venules as a surrogate marker for T cell inflamed tumor microenvironment and prognosis in gastric cancer

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.4884-4884

2019

Link zum Volltext

Verfügbarkeit prüfen

Phase II study of sitravatinib in combination with tislelizumab in patients with advanced biliary tract cancer who have failed to at least 1 prior systemic treatment: Trial in progress

Journal of clinical oncology, 2022-02, Vol.40 (4_suppl), p.TPS490-TPS490

2022

Link zum Volltext

Verfügbarkeit prüfen

A multi-institutional, single-arm, phase II trial of neoadjuvant modified-FOLFIRINOX for resectable pancreatic ductal adenocarcinoma

Journal of clinical oncology, 2022-02, Vol.40 (4_suppl), p.TPS624-TPS624

2022

Link zum Volltext

Verfügbarkeit prüfen

A multi-institutional, single-arm, phase II trial of neoadjuvant modified-FOLFIRINOX for resectable pancreatic ductal adenocarcinoma

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.715-715

2023

Link zum Volltext

Verfügbarkeit prüfen

IMbrave151: A phase 2, randomized, double-blind, placebo-controlled study of atezolizumab with or without bevacizumab in combination with cisplatin plus gemcitabine in patients with untreated, advanced biliary tract cancer

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.491-491

2023

Link zum Volltext

Verfügbarkeit prüfen

Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma

Journal of clinical oncology, 2020-02, Vol.38 (4_suppl), p.550-550

2020

Link zum Volltext

Verfügbarkeit prüfen

ARID1A mutation to predict disease progression during first-line chemotherapy in biliary tract cancer patients

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.4105-4105

2021

Link zum Volltext

Verfügbarkeit prüfen

Randomized phase II study of nalicap (nal-IRI/capecitabine) compared to NAPOLI (nal-IRI/5-FU/LV) in gemcitabine-pretreated advanced pancreatic cancer: Trial-in-progress

Journal of clinical oncology, 2022-02, Vol.40 (4_suppl), p.TPS621-TPS621

2022

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2092: Artificial intelligence technology enables a rational development of a potent immunotherapeutic agent

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.2092-2092

2020

Link zum Volltext

Verfügbarkeit prüfen

Different organ-specific response to nivolumab to determine the survival outcome of patients with advanced hepatocellular carcinoma (aHCC)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.4584-4584

2020

Link zum Volltext

Verfügbarkeit prüfen

Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: Multicenter study of the Korean Cancer Study Group (KCSG)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.4624-4624

2020

Link zum Volltext

Verfügbarkeit prüfen

Randomized phase II trial comparing 4 doublets as a front-line treatment in Asian patients with recurrent/metastatic gastric cancer

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.4063-4063

2016

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Effect of STING agonist on tumor immune microenvironment of non-inflamed lung cancer and efficacy of immune checkpoint blockade

Abstract 5637: Combination of oncolytic vaccinia virus and immune checkpoint blockade overcomes resistance to immunotherapy in renal cell carcinoma

Abstract A061: STING, an immune biomarker for colorectal cancer

Phase II trial of second-line regorafenib in patients with unresectable hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab: REGONEXT trial

Efficacy of nivolumab and ipilimumab in patients with hepatocellular carcinoma with prior immune-checkpoint inhibitor treatment

Organ-specific responses to atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma

Efficacy and safety of nab-paclitaxel plus gemcitabine-cisplatin (GemCis/nab-P) in Korean patients with advanced biliary tract cancers (aBTC): Multicenter retrospective analysis

Clinical feasibility of curative surgery after nab-paclitaxel plus gemcitabine-cisplatin chemotherapy in patients with locally advanced cholangiocarcinoma

Correlation of high serum interleukin-6 with clinical outcome and T cell response in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab

Artificial intelligence (AI)-powered immune phenotyping to predict outcomes of immuno-oncology (IO)-based regimens in hepatocellular carcinoma (HCC)

Abstract 4884: Intratumoral high endothelial venules as a surrogate marker for T cell inflamed tumor microenvironment and prognosis in gastric cancer

Phase II study of sitravatinib in combination with tislelizumab in patients with advanced biliary tract cancer who have failed to at least 1 prior systemic treatment: Trial in progress

A multi-institutional, single-arm, phase II trial of neoadjuvant modified-FOLFIRINOX for resectable pancreatic ductal adenocarcinoma

A multi-institutional, single-arm, phase II trial of neoadjuvant modified-FOLFIRINOX for resectable pancreatic ductal adenocarcinoma

IMbrave151: A phase 2, randomized, double-blind, placebo-controlled study of atezolizumab with or without bevacizumab in combination with cisplatin plus gemcitabine in patients with untreated, advanced biliary tract cancer

Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma

ARID1A mutation to predict disease progression during first-line chemotherapy in biliary tract cancer patients

Randomized phase II study of nalicap (nal-IRI/capecitabine) compared to NAPOLI (nal-IRI/5-FU/LV) in gemcitabine-pretreated advanced pancreatic cancer: Trial-in-progress

Abstract 2092: Artificial intelligence technology enables a rational development of a potent immunotherapeutic agent

Different organ-specific response to nivolumab to determine the survival outcome of patients with advanced hepatocellular carcinoma (aHCC)

Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: Multicenter study of the Korean Cancer Study Group (KCSG)

Randomized phase II trial comparing 4 doublets as a front-line treatment in Asian patients with recurrent/metastatic gastric cancer

Suchergebnisse filtern